Targeting breast cancer stem cells
靶向乳腺癌干细胞
基本信息
- 批准号:10093979
- 负责人:
- 金额:$ 91.55万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-02-01 至 2023-01-31
- 项目状态:已结题
- 来源:
- 关键词:BloodBlood specimenCellsClinical TrialsCytotoxic agentDevelopmentDrug TargetingEpigenetic ProcessEpithelialGenetic HeterogeneityGenetic studyGenomicsHeterogeneityIn VitroLaboratoriesMalignant NeoplasmsMediatingMesenchymalMethodologyMolecularMutationNeoplasm MetastasisPathway interactionsPatient-Focused OutcomesPatientsPhenotypePopulationProcessPropertyProteomicsRadiation therapyResistanceResolutionRoleTechnologyTherapeuticTimeTreatment Efficacycancer biomarkerscancer stem cellcancer therapycytotoxic radiationimproved outcomemalignant breast neoplasmmolecular targeted therapiesmouse modelnew technologynovelpatient derived xenograft modelpublic health relevancestem cellstherapy resistanttumortumor growthtumor microenvironment
项目摘要
DESCRIPTION (provided by applicant): Tumor cellular heterogeneity presents a formidable challenge to the development of effective cancer therapeutics. In addition to well-studied genetic heterogeneity resulting from mutation and clonal selection, there is mounting evidence for a fundamental role of epigenetic heterogeneity in mediating therapeutic resistance. Epigenetic mechanisms regulating cellular differentiation generate hierarchically organized cellular clones within tumors. At the apex of these hierarchies are cancer stem cells (CSCs) which drive tumor growth and metastasis. CSCs are endowed with phenotypic plasticity enabling them to transition between mesenchymal and epithelial-like states, processes regulated by the tumor microenvironment. CSCs also display intrinsic resistance to cytotoxic agents and radiation therapy and also may be resistant to molecularly targeted therapies aimed at bulk tumor populations. CSC heterogeneity, plasticity, and therapeutic resistance have profound implications for development of effective cancer therapies.
Over the past decade, our laboratory has identified markers for CSCs in breast cancer, as well as other tumor types and developed in vitro and mouse models that have facilitated isolation and characterization of these cells. We have identified a number of cell intrinsic and microenvironmentally driven pathways that regulate these cells facilitating development of CSC-targeting drugs, a number of which have now entered clinical trials. We propose to extend these studies by applying single-cell genomic and proteomic technologies to characterize CSC heterogeneity at single-cell resolution. We will develop novel technologies to capture and molecularly interrogate circulating CSCs in molecularly annotated PDX models, as well as in primary patient blood samples. These technologies will facilitate more precise selection of agents to target CSCs, as well as facilitating real time assessment of therapeutic efficacy for patients on CTC targeting clinical trials. The successful targeting of CSCs has the potential to significantly improve the outcomes of patients with breast cancer, as well as other malignancies.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MAX S. WICHA其他文献
MAX S. WICHA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MAX S. WICHA', 18)}}的其他基金
相似海外基金
THALASSEMIA DATA AND BLOOD SPECIMEN COLLECTION SYSTEM
地中海贫血数据和血液样本采集系统
- 批准号:
7607252 - 财政年份:2007
- 资助金额:
$ 91.55万 - 项目类别:
THALASSEMIA DATA AND BLOOD SPECIMEN COLLECTION SYSTEM
地中海贫血数据和血液样本采集系统
- 批准号:
7380732 - 财政年份:2006
- 资助金额:
$ 91.55万 - 项目类别:
THALASSEMIA DATA AND BLOOD SPECIMEN COLLECTION SYSTEM
地中海贫血数据和血液样本采集系统
- 批准号:
7204708 - 财政年份:2005
- 资助金额:
$ 91.55万 - 项目类别:
2D SYMBOLOGY FOR CLINICAL BLOOD SPECIMEN HANDLING
临床血液样本处理的二维符号
- 批准号:
2286334 - 财政年份:1996
- 资助金额:
$ 91.55万 - 项目类别:
CLINICAL LABORATORY BLOOD SPECIMEN INSPECTION SYSTEM
临床实验室血液标本检测系统
- 批准号:
2030324 - 财政年份:1996
- 资助金额:
$ 91.55万 - 项目类别: